Gray Foundation’s Neurocrine Biosciences NBIX Stock Holding History

Gray Foundation’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.37M	Hold	37,800	–	–	1.4%	8
2026 Q1	$4.98M	Hold	37,800	–	–	1.26%	10
2025 Q4	$5.36M	Buy	+37,800	New	+$5.48M	1.35%	10

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gray Foundation's NBIX Position: Q2 2026 in Review

Gray Foundation held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 37,800 shares worth $6.37M. The position accounts for 1.4% of the portfolio, ranked #8.

Gray Foundation first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Gray Foundation held 37,800 shares of Neurocrine Biosciences worth $6.37M as of Q2 2026.
Gray Foundation left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 1.4% of Gray Foundation's portfolio in Q2 2026, its #8 holding.
Gray Foundation first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Gray Foundation's 13F filing for Q2 2026, filed 5 Aug 2026.